Bausch Health Companies Inc. (TSX:BHC)
Market Cap | 3.80B |
Revenue (ttm) | 13.85B |
Net Income (ttm) | -66.19M |
Shares Out | n/a |
EPS (ttm) | -0.18 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 377,161 |
Average Volume | 398,002 |
Open | 10.69 |
Previous Close | 10.75 |
Day's Range | 10.20 - 10.75 |
52-Week Range | 5.45 - 15.43 |
Beta | 0.68 |
RSI | 52.99 |
Earnings Date | Feb 20, 2025 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]
Financial Performance
In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.
Financial numbers in USD Financial StatementsNews
Bausch Health Companies Inc. (BHC) J.P. Morgan Global Leveraged Finance Conference Transcript

Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room
Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The co...
Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)

Alibaba, Hasbro, Shake Shack, Bausch Health And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones falling over 1% on Thursday. Shares of Alibaba Group Holding Limited (NYSE: BABA) rose sharply during Thursday's session after the company reported third-qu...
Q4 2024 Bausch Health Companies Inc Earnings Call Transcript
Q4 2024 Bausch Health Companies Inc Earnings Call Transcript
Bausch Health projects $4.95B-$5.1B revenue for 2025 with focus on growth and innovation
Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript
Bausch Health Q4 2024 Earnings: Revenue Surpasses Estimates at $2. ...
Bausch Health Q4 2024 Earnings: Revenue Surpasses Estimates at $2.56 Billion, EPS Falls Short at $0.25

Bausch Health Shares Climb On Better-Than-Expected Q4 Revenue, Strong Forward Guidance
Bausch Health Companies Inc. (NYSE: BHC) reported its fourth-quarter results after Wednesday's closing bell. Here's a look at the details from the report. The Details: Bausch Health Companies reporte...

Bausch Health Announces Fourth Quarter and Full-Year 2024 Results
Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated Reve...

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-qua...

Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference...

Skincare Devices Market and Competition Analysis 2025-2030, Featuring 42 Major Companies Including Alma Lasers, Bausch Health Companies, Lumenis, Merz Pharma & More
Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth

Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology...

Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million
New On The Block PharmChem, Inc. (OTC: PCHM), the go-to name for drug-detecting sweat patches, is officially exploring strategic alternatives (i.e., mergers, acquisitions, or an outright sale). So fa...
Bausch Health cut to hold by Jefferies over B+L update

Contact lens maker Bausch + Lomb rules out take-private deal
Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday.

Bausch Health Provides Update on Strategic Alternatives
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives throu...

Bausch + Lomb Provides Update on Potential Sale
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following update on...

Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, Febr...

Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conferen...

Bausch Health Swaps Out Advisers After Years of Debt, Sale Talks
Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long effort to tackle some of its approximately $20 billion dollars of debt and enabl...

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarte...

Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for...